Hemab Therapeutics Holdings Inc (COAG) (Q3 2026) Earnings Call Highlights: Pivotal SOLARA Trial ...
Hemab Therapeutics to Participate in Upcoming Investor Conferences
Hemab (COAG) Q3 2026 Earnings Call Transcript
What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call
Hemab Therapeutics Holdings (NASDAQ:COAG) Posts Wider Q3 Loss as Pipeline Catalysts Lift Stock
Hemab Therapeutics Holdings, Inc. (COAG) Q3 2026 Earnings Call Transcript
Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Hemab Therapeutics Hldgs Q3 2026 Earnings Call Transcript
Hemab Therapeutics Hldgs Q3 EPS $(0.58) Misses $(0.52) Estimate
Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia
LifeSci Capital Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $65
Hemab Therapeutics Initiates SOLARA, Pivotal Phase 3 Trial Evaluating Sutacimig As Potential Prophylactic Treatment For People With Glanzmann Thrombasthenia
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
Hemab Therapeutics To Present Two Presentations At American Society Of Hematology Annual Meeting
Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026
JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70
Rodman & Renshaw Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $56
Hemab Therapeutics: The Market Is Pricing One Rung Of A Four-Rung Ladder
Hemab Therapeutics Holdings (COAG) Joins Russell Indices, Is The Stock Still Trading At A Discount?
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.